Titan Pharmaceuticals Reports Fourth Quarter And Full Year 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
Titan Pharma (TTNP) Reports In-Line Q4 EPS, Revenues Beat
March 30, 2020 4:05 PM EDTTitan Pharma (NASDAQ: TTNP) reported Q4 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $920 thousand.
"Throughout 2019, we focused on initiatives to successfully transition to a commercial-stage company," said Titan's President and CEO, Sunil Bhonsle. "I am very pleased with our team's progress during 2019, which, among other things, includes executing arrangements with multiple top tier specialty pharmacy companies, establishing a new patient services 'hub,' and obtaining insurance coverage from a broad range of third party payors all of which served to... More
